Intellia Therapeutics Stock News

Positive results achieved in phase 1 study NTLA-2001 to treat ATTR-PN patients; 87% reduction of serum TTR levels in 3 patients using 0.3 mg/kg and then 52% reduction using 0.1 mg/kg. Additional resul

Intellia Therapeutics, Inc. (NASDAQ:NTLA) has been given an average rating of Buy by the eighteen analysts that are covering the stock, MarketBeat.com reports. One analyst has rated the stock with a sell rating, three have given a hold rating and fourteen have assigned a buy rating to the company. The average 12-month target price among []

Intellia (NTLA) doses the first patient in a phase I/II study to evaluate NTLA-2002 as a single-dose therapy for preventing attacks in patients having hereditary angioedema.

Gene therapy biotech Intellia Therapeutics has dosed its first patient with genome editing candidate NTLA-2002, its drug candidate for hereditary angioedema, a rare genetic condition that causes swelling under the skin. The drug candidate has been under development as a single-dose gene therapy to prevent HAE attacks by inactivating the

NTLA-2002 is the first single-dose genome editing therapeutic candidate designed to prevent angioedema attacks in patients with hereditary angioedema (HAE) to enter clinical study NTLA-2002 is the first single-dose genome editing therapeutic candidate designed to prevent angioedema attacks in patients with hereditary angioedema (HAE) to enter clinical study

Shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA) have been assigned an average rating of Buy from the eighteen brokerages that are currently covering the firm, MarketBeat.com reports. One analyst has rated the stock with a sell recommendation, three have assigned a hold recommendation and fourteen have assigned a buy recommendation to the company. The average 1-year []

Capital Advisors Inc. OK increased its holdings in Intellia Therapeutics, Inc. (NASDAQ:NTLA) by 2,006.9% in the 3rd quarter, HoldingsChannel reports. The institutional investor owned 44,245 shares of the companys stock after buying an additional 42,145 shares during the period. Capital Advisors Inc. OKs holdings in Intellia Therapeutics were worth $5,935,000 as of its most recent []

When the market looks uncertain investors should flock to industry leaders.

In trading on Tuesday, the ARK Genomic Revolution ETF is outperforming other ETFs, up about 8.1% on the day. Components of that ETF showing particular strength include shares of Intellia Therapeutics, up about 18.1% and shares of Fate Therapeutics, up about 15.6% on the day. And underperforming other ETFs today is the First Trust Preferred [] The post Tuesdays ETF Movers: ARKG, FPE appeared first on UK Stocks, Forex, Commodities, Crypto, Live Market News- Daily Forex News .

While markets are cautiously optimistic on the Omicron variant, these health care stocks are still hard at work.

Marotta Asset Management purchased a new position in shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA) in the 3rd quarter, HoldingsChannel.com reports. The institutional investor purchased 1,500 shares of the companys stock, valued at approximately $201,000. Several other hedge funds and other institutional investors have also bought and sold shares of NTLA. Advisory Services Network LLC acquired []

RMB Capital Management LLC lessened its position in shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA) by 3.0% in the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 17,228 shares of the companys stock after selling 527 shares during the period. RMB Capital Management LLCs []

Related Stocks: LHX , AON , CVS , LH , NVDA , BABA , GE , DFAS , NOV , GME , PUK , NTLA , CMI , WU , HPQ , WHR , THO , MRK , PROS , QTNT , CORE , FPI , WD , SCI ,

Management has given hints for continued impressive results from its lead NTLA-2001 program. NTLA-2001 has been approved for ATTR patients with cardiomyopathy.